Investigational drug · Phase 3
Sonelokimab
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hidradenitis Suppurativa, Arthritis, Psoriatic.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
4 still active
All registered trials
11
Any phase or sponsor naming "Sonelokimab"
First trial start
2024
May 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sonelokimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa
- Arthritis, Psoriatic
Approved drugs for the same conditions: Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Sonelokimab" as an intervention, largest first.
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisPivotal-lookingEnrolling by invitation
MoonLake Immunotherapeutics AGIndustry
NCT07223138 · 1,560 participants (planned) · Start Nov 13, 2025 · Primary completion Feb 4, 2028
Drug: Sonelokimab · For: Arthritis, Psoriatic
Sites: Avondale, Arizona; Mesa, Arizona; Phoenix, Arizona · 18 sites in all
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugPivotal-lookingActive, not recruiting
MoonLake Immunotherapeutics AGIndustry
NCT06641076 · 960 participants (planned) · Start Oct 15, 2024 · Primary completion May 28, 2026
Drug: Sonelokimab; Placebo · For: Arthritis, Psoriatic
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 182 sites in all
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingEnrolling by invitation
MoonLake Immunotherapeutics AGIndustry
NCT07007637 · 835 participants (planned) · Start Jun 27, 2025 · Primary completion Jun 13, 2028
Drug: Sonelokimab · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; North Little Rock, Arkansas; Los Angeles, California · 166 sites in all
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePivotal-lookingActive, not recruiting
MoonLake Immunotherapeutics AGIndustry
NCT06641089 · 600 participants (planned) · Start Oct 15, 2024 · Primary completion Jan 4, 2027
Drug: Sonelokimab; Placebo and 1 more · For: Arthritis, Psoriatic
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 143 sites in all
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
MoonLake Immunotherapeutics AGIndustry
NCT06411899 · 422 participants · Start May 15, 2024 · Primary completion Sep 2, 2025
Drug: Sonelokimab; Placebo · For: Hidradenitis Suppurativa
Sites: Los Angeles, California; Northridge, California; Sacramento, California · 109 sites in all
- Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
MoonLake Immunotherapeutics AGIndustry
NCT06411379 · 418 participants · Start May 14, 2024 · Primary completion Aug 14, 2025
Drug: Sonelokimab; Placebo · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; North Little Rock, Arkansas; Fountain Valley, California · 106 sites in all
- A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe PsoriasisPivotal-lookingCompleted
Bond Avillion 2 Development LPIndustry
NCT03384745 · 313 participants · Start Jul 31, 2018 · Primary completion Jun 20, 2019
Drug: M1095 (Sonelokimab); Placebo and 1 more · For: Psoriasis
Sites: Birmingham, Alabama; San Diego, California; DeLand, Florida · 60 sites in all
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
MoonLake Immunotherapeutics AGIndustry
NCT05322473 · 234 participants · Start Apr 25, 2022 · Primary completion May 9, 2023
Drug: Sonelokimab (M1095); Adalimumab · For: Hidradenitis Suppurativa
Sites: Fountain Valley, California; Los Angeles, California; Miami, Florida · 57 sites in all
- Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisPivotal-lookingCompleted
MoonLake Immunotherapeutics AGIndustry
NCT05640245 · 207 participants · Start Dec 13, 2022 · Primary completion Sep 5, 2023
Drug: Sonelokimab; Placebo and 1 more · For: Arthritis, Psoriatic
Sites: Rancho Mirage, California; Duncansville, Pennsylvania; Pleven, Bulgaria · 42 sites in all
- An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an AutoinjectorPivotal-lookingCompleted
MoonLake Immunotherapeutics AGIndustry
NCT06994936 · 120 participants · Start Jun 5, 2025 · Primary completion Nov 1, 2025
Drug: Sonelokimab; Sonelokimab · For: Relative Bioequivalence
Sites: London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Sonelokimab, a novel interleukin 17A-inhibiting and interleukin 17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: A global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA).
Kimball AB, Bechara FG, Porter ML, et al. · J Am Acad Dermatol 2026
- IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.
AbuJwaid YK, Assi AK, Amro AM, et al. · Front Immunol 2026
- Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety.
Hagino T, Kanda N · J Dermatol 2026
- Decoding biological drug names in dermatology: The post-2022 WHO nomenclature revision and its implications for clinical practice.
Singh S, Sharma YK, Gupta A · J Am Acad Dermatol 2026
- Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review.
Osunbor O, Nkeck JR, Adebajo AO · Expert Opin Investig Drugs 2026
- The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis.
Katsouli O, Lainis V, Goules AV, et al. · Mediterr J Rheumatol 2026
Also in development for Hidradenitis Suppurativa
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MAS825ArumakimigPhase 24 trials
Novartis · NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome
- EltrekibartLY3041658Phase 22 trials
Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa
- HB0043Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Acne Vulgaris, Hidradenitis Suppurativa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.